Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00045357 · ClinicalTrials.gov registry record · Phase 1
Biological Therapy in Treating Patients With Metastatic Melanoma
A Phase 1 study, sponsored by Fred Hutchinson Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
NCT00045357 is a Phase 1 study that has completed, run by Fred Hutchinson Cancer Center. The registered enrollment target is 18 participants.
The verdict
NCT00045357, a Phase 1 study, has completed, sponsored by Fred Hutchinson Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
RATIONALE: Biological therapies use different ways to stimulate the immune system and stop tumor cells from growing. Treating a person's white blood cells in the laboratory and reinfusing them may cause a stronger immune response and kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of biological therapy in treating patients who have metastatic melanoma.
Interventions
- BIOLOGICAL therapeutic autologous lymphocytes
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2001-11 |
| Est. Completion | 2008-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00045357
The ClinicalTrials.gov registry entry for NCT00045357 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Fred Hutchinson Cancer Center, which has 483 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which therapeutic autologous lymphocytes is the first listed.
NCT00045357 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00045357 about?
NCT00045357 is a clinical study titled "Biological Therapy in Treating Patients With Metastatic Melanoma". RATIONALE: Biological therapies use different ways to stimulate the immune system and stop tumor cells from growing. Treating a person's white blood cells in the laboratory and reinfusing them may cause a stronger immune response and kill more tumor cells. PURPOSE: Phase I trial to study the effect...
What is the current status of trial NCT00045357?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2001-11. Estimated completion is 2008-08.
What interventions are being tested in trial NCT00045357?
The interventions under investigation include: therapeutic autologous lymphocytes (BIOLOGICAL).
Who is sponsoring clinical trial NCT00045357?
This trial is sponsored by Fred Hutchinson Cancer Center, which has 483 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.